NewAmsterdam Posts $64.1M Q2 Loss, Holds $678M Cash; CAO Kooij Exits with Severance
NAMS sits 30% above its 52-week low of $21.234.
Summary
NewAmsterdam Pharma's Q2 2026 loss widened to $64.1M on higher R&D spending, while its $678M cash position funds operations through upcoming regulatory and clinical milestones. The company also disclosed a severance deal with its departing CAO.
Key Events · Earnings and Guidance · NAMS
-
Q2 Loss Widens on R&D Spend
Net loss of $64.1M vs $17.4M in Q2 2025, driven by a 52% increase in R&D expenses to $41.7M as clinical programs advance.
-
Strong Cash Position
Cash, cash equivalents, and marketable securities totaled $678.3M at June 30, 2026, providing runway through the PREVAIL CVOT interim analysis and potential EU launch.
-
CAO Departure and Severance
Chief Accounting Officer Louise Kooij will depart under a settlement agreement providing 12 months' salary as severance and continued equity vesting through January 2027, with extended option exercisability.
-
PREVAIL Interim Analysis Planned
Company plans a blinded interim analysis of the PREVAIL cardiovascular outcomes trial in Q4 2026, with a DSMB recommendation expected in Q1 2027.
Analysis · NAMS · Life Sciences
A 52% surge in R&D spending pushed NewAmsterdam Pharma's Q2 net loss to $64.1 million, as the company advances obicetrapib toward a potential EU approval. With $678.3 million in cash and equivalents, the runway extends through key catalysts, including a PREVAIL CVOT interim analysis later this year. In a separate disclosure, the filing details a settlement agreement with departing Chief Accounting Officer Louise Kooij, who will receive 12 months' salary as severance and continued vesting of equity awards through January 2027 — a notable retention mechanism for a senior finance executive during a critical pre-commercial period.
At the time of this filing, NAMS was trading at $27.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $21.23 to $42.21. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.